---
title: "Axsome Therapeutics, Inc. (AXSM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AXSM.US.md"
symbol: "AXSM.US"
name: "Axsome Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T10:12:23.046Z"
locales:
  - [en](https://longbridge.com/en/quote/AXSM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AXSM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AXSM.US.md)
---

# Axsome Therapeutics, Inc. (AXSM.US)

## Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.axsome.com](https://www.axsome.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 52 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 63.88% |  |
| Net Profit YoY | 32.33% |  |
| P/B Ratio | 213.68 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11664385159.22 |  |
| Revenue | 708236000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -349.38% | E |
| Profit Margin | -26.59% | E |
| Gross Margin | 92.30% | A |
| Revenue YoY | 63.88% | A |
| Net Profit YoY | 32.33% | B |
| Total Assets YoY | 19.60% | A |
| Net Assets YoY | 2.60% | C |
| Cash Flow Margin | 37.56% | D |
| OCF YoY | 63.88% | A |
| Turnover | 1.08 | A |
| Gearing Ratio | 92.35% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Axsome Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "63.88%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "32.33%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "213.68",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11664385159.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "708236000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-349.38%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-26.59%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "92.30%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "63.88%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "32.33%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "19.60%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.60%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "37.56%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "63.88%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.08",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "92.35%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -61.94 | 222/190 | - | - | - |
| PB | 213.68 | 195/190 | 109.49 | 97.62 | 86.77 |
| PS (TTM) | 16.47 | 126/190 | 15.12 | 12.90 | 11.96 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **21**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 17 | 81% |
| Overweight | 3 | 14% |
| Hold | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 226.67 |
| Highest Target | 281.00 |
| Lowest Target | 200.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AXSM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AXSM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AXSM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AXSM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**